ClinicalTrials.gg
RecruitingNCT07613918Updated Aug 27, 2026

Brain Blood Flow and Cerebral Autoregulation Monitoring in Critically Ill Children

An observational study in Critical Illness, Pediatric Critical Illness and Respiratory Failure, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 1 Day to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-27.

Primary conditionCritical Illness(the registry's first term)UnverifiedIs this wrong?Critical Illness is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by University of Wisconsin, Madison · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
125
Ages
1 Day to 17 Years
Sex
All
01

Study summary

This study uses a non-invasive (external) ultrasound test called Transcranial Doppler (TCD) to measure how blood flows through the major arteries of the brain of children receiving care in the Pediatric Intensive Care Unit (PICU). TCD is already used for clinical reasons in many children, but it is not part of routine monitoring for every critically ill child. By using TCD, the investigators hope to better understand how brain blood flow changes during illness. They will also track children's functional status from before their illness to the time of PICU discharge to explore how brain blood flow patterns relate to neurological outcomes.125 participants will be enrolled and will be on study while in the PICU, estimated to be 3-14 days.

Read the detailed description

Current clinical management of hemodynamics in critically ill children relies primarily on systemic parameters (e.g., blood pressure, heart rate) rather than direct assessment of cerebrovascular regulation. This approach may overlook individual variations in cerebral autoregulation (CA) capacity, potentially leading to suboptimal cerebral perfusion.

By prospectively evaluating TCD-derived CA indices in intubated pediatric patients with arterial blood pressure monitoring, this study aims to:

  1. Establish normative Cerebral blood flow velocity (CBFV) ranges for critically ill children
  2. Describe CBFV patterns across critically ill pediatric populations with varying neurologic risk profiles
  3. Characterize the prevalence of CA dysfunction in a heterogeneous PICU population
  4. Explore associations between CA/CBFV and functional outcomes

These data could:

  1. Provide age-stratified CBFV reference values for the PICU setting
  2. Identify patients at highest risk of neurological morbidity using population-specific thresholds
  3. Inform future trials of autoregulation-guided hemodynamic management
02

Conditions studied

  • Critical Illness
  • Pediatric Critical Illness
  • Respiratory Failure
  • Traumatic Brain Injury
  • Cardiac Arrest

Keywords

  • PICU
  • infant
  • Transcranial Doppler Assessment
  • Cerebral Autoregulation
  • Blood Flow Velocity
  • children
  • mechanical ventilation
  • neurocritical care
  • pulsatility index
  • Mean flow index
  • neonate
  • pediatric critical care
03

In context

Critical Illness Unverified

1,787 studies on the registry are indexed under Critical Illness; 445 are open to participants now.

This study's planned enrollment of 125 is below the median of 140 across 816 observational studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

University of Wisconsin, Madison is the lead sponsor of 1,190 studies on the registry; 181 are open to participants now.

Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.

Compared within Critical Illness, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
1 Day to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Mechanically ventilated pediatric patients (1 day-17.5 years) admitted to the PICU who meet eligibility criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has at least one Parent or Legal Guardian who is willing and able to provide in English
  • Mechanically ventilated (Endotracheal tube)
  • Indwelling arterial catheter
  • Current patient in the American Family Children's Hospital PICU.
  • 1 day to 17.5 years of age

Exclusion criteria

Exclusion Criteria:

  • Subjects with a known or obvious anatomic barrier preventing safe application of the transcranial Doppler probe (e.g., cranial dressings, cranial fixation hardware, ventricular access devices positioned over insonation sites, or bilateral craniectomies)
  • Patient with known chronic hypertension
  • Admission FSS score > 16
  • Tracheostomized patient
  • The designated sub-investigator (Dr. Talal Al Hendawi) and PI (Dr. Neil Munjal) are unavailable to perform the Transcranial Doppler scan at the time of eligibility. All study scans are performed by either Dr. Al Hendawi or Dr.Munjal to ensure standardization and data integrity. Therefore, if they are unavailable (e.g., due to clinical service, leave, or other scheduling constraints), the patient will not be enrolled in the study.
  • Not suitable for study participation due to other reasons at the discretion of the investigators
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
125 participants (estimated)
Patient registry
No

Groups and cohorts

  • PICU Patients

    Mechanically ventilated pediatric patients (1 day-17.5 years) admitted to the PICU.

    Device: Transcranial Doppler

Interventions

  • DeviceTranscranial Doppler

    TCD measurements synchronized to arterial blood pressure and ventilatory data, performed once daily for up to 5 days during PICU admission plus one additional pre-extubation scan if applicable, approximately 30 minutes each. Bilateral middle cerebral artery (MCA) insonation performed at each session.

    Also known as: TCD

06

What researchers measure

Primary outcomes

  1. Change in Functional Status Scale (FSS) from baseline to PICU discharge

    To assess the relationship between cerebral autoregulation and neurological outcomes in critically ill pediatric patients, FSS will be measured. FSS has 6 domains: mental status, sensory, communication, motor function, feeding, and respiratory. FSS is scored from 6 to 30, higher scores are indicative of more severe dysfunction.

    Time frame: Baseline FSS reflects pre-morbid functional status as reported by parents/guardians at enrollment; follow-up FSS assessed at PICU discharge (estimated 3-14 days)

Secondary outcomes

  1. Mean Flow Index (Mx)

    Mean Flow Index (Mx) will serve as the primary exposure variable in multivariable regression analyses relating cerebral autoregulation status to functional outcome, and will additionally be characterized across PICU subpopulations.

    Time frame: data collected while in PICU, from consent (baseline) to discharge (estimated 3-14 days)

  2. Percent successful exams (complete bilateral MCA data)

    Feasibility metric reflecting the proportion of TCD sessions yielding complete bilateral MCA data, used to assess protocol feasibility and sonographic success rates in the PICU setting.

    Time frame: data collected while in PICU, from consent (baseline) to discharge (estimated 3-14 days)

  3. Time per exam (min)

    Feasibility metric reflecting total time required per TCD session, used to assess protocol efficiency and burden on clinical care.

    Time frame: data collected while in PICU, from consent (baseline) to discharge (estimated 3-14 days)

  4. Mean CBFV

    To describe cerebral blood flow velocity patterns in critically ill pediatric patients, mean CBFV will be measured.

    Time frame: data collected while in PICU, from consent (baseline) to discharge (estimated 3-14 days)

  5. Age-stratified CBFV values across pre-specified clinical subgroups (TBI, cardiac arrest, ECMO)

    Time frame: data collected while in PICU, from consent (baseline) to discharge (estimated 3-14 days)

  6. Age-stratified Mx values across pre-specified clinical subgroups (TBI, cardiac arrest, ECMO)

    Time frame: data collected while in PICU, from consent (baseline) to discharge (estimated 3-14 days)

07

Study locations

1 of 1 sites recruiting
  • American Family Children's Hospital PICU
    Madison, Wisconsin 53792, United States
    Recruiting
    • Talal Al Hendawi, MD · Sub investigator
    • Neil Munjal, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for May 2028, 21 months after the start.

Of 441 non-industry observational studies under Critical Illness, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 21 months is close to that.

Counting every sponsor, half of 444 studies reached it within 23 months; a quarter within 12 and three quarters within 46.

Critical Illness covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
May 29, 2026
StartActual
Aug 3, 2026
Primary completionEst.
May 2028
CompletionEst.
May 2028
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07613918
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Aug 3, 2026
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Aug 27, 2026

Study contacts

Meg Baker
Contact
meg.baker@wisc.edu
meg.baker@wisc.edu
Neil Munjal, MD
principal investigator · UW School of Medicine and Public Health

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion